Many People Receiving Treatment for RA Still Report Discomfort
Despite all these options, a study published in September 2019 in Rheumatology and Therapy found that almost 75 percent of RA patient respondents in a survey were dissatisfied with their treatments, reporting distressful symptoms such as fatigue (82 percent), pain (76 percent), and physical limitations (75 percent), which had a negative influence on quality of life. While receiving treatment, 37 percent of respondents still had moderate disease activity, and 33 percent had high disease activity. Only 16 percent achieved remission and 13 percent reported low disease activity with treatment, the researchers say. The study was based on a survey of 258 patients with RA who were enrolled in ArthritisPower, the online patient research registry of CreakyJoints, and supported by Eli Lilly and Company. Forty-three percent of respondents reported daily or almost daily use of prescription pain medication; 44 percent reported a current flare.
Rheumatologist Surprised by the Extent of Dissatisfaction
“I was a little bit surprised by those numbers,” says Jeffrey Curtis, MD, MPH, senior author of the study and professor of medicine in rheumatology and immunology at the University of Alabama at Birmingham. “Biologics and targeted therapies may result in patients doing better, but that doesn’t mean that patients are necessarily doing well." Biologic drugs target immune system proteins associated with inflammation, according to the Arthritis Foundation. “I wouldn’t have expected 75 percent [dissatisfaction], but I know that even when pain is well-controlled, you can have symptoms from other issues,” adds Nilanjana Bose, MD, MBA, a rheumatologist with Rheumatology Center of Houston who wasn’t involved in the study. “Patients tell you overall how they feel, and there is always the possibility that it’s not from their RA or it’s just at that moment in time. There are a lot of variables.”
Why RA Patients Are Disappointed With Treatment Results
Experts hypothesize about why there is this disconnect between treatment and perceived results on the part of patients:
Patients Don’t Come in Early Enough in the Disease Progression
Early diagnosis is critical, before joint damage occurs. “Damage to the joint is irreversible. No therapy can put that back. However, patients can be skittish about medicines, so they don’t start early enough. After that happens, I can put them on a medication that will improve symptoms, but it won’t bring them back to where they were pre-disease. This leaves a lot of folks not satisfied with where they end up,” says Dr. Curtis.
Lack of Communication Between the Person Living With the Disease and the Person Caring for Them
Doctors need to walk the patient through the whole process and lay out a plan of action and expectations: How does the drug work? How long will the patient need to be on it? How effective is it? What are the side effects? What are the goals? “When I start a patient on a new treatment, I always go over the drug and have the patient come back soon for a check-in. If there are issues, we try to understand if it’s from the disease, the drug, or something else. Discussion needs to be happening at every step. Patients feel better when they have information and believe that someone is listening to them,” says Dr. Bose.
People Living With the Disease May Need to Become More Involved and Proactive in Treatment
Curtis continues, “I would advocate for more shared decision-making. Patients need to understand that every time we change something, there is a choice — even not changing something is a choice to be made. I don’t want patients to feel they are on the passive end of being told treatment choices.” He recommends that patients become more proactive by asking themselves and their doctors, “Is this the best that I can do?” Bose finds that given the opportunity, most patients want to learn, want information, and want to manage themselves better.
The Change May Not Be in the Medication but in Lifestyle
Achieving better results may not necessarily mean changing drugs; it can also involve a better diet, low-impact exercise, cognitive behavioral therapy, quitting smoking, or seeking help with comorbidities such as depression. If their physicians aren’t addressing this, patients should start the conversation. “We need to see the patient as more than their disease and take a more holistic approach that looks at the total patient,” says Curtis. “Clinicians should ask how satisfied their patients are with how they are doing and find the things that will really make a difference in people’s lives to improve pain, function, mobility, and sleep. It’s not necessarily changing a drug. That sometimes gets overlooked.”
Many Variables Can Be Responsible for Patient-Reported Outcomes
Theory and practice don’t always go hand in hand. In practice, there are always gray zones, says Bose: “Is the drug not working or is something else going on, such as stress at home, not following protocol, or is comorbid osteoarthritis acting up? Do the patients follow up, or do they cancel appointments? ”
Patients May Not Follow Treatment Protocol Because of Financial Issues
Research published in September 2019 by GoodRX reported that the cost of RA medication has doubled in five years. The cost of biologics has doubled since 2014; non-biologics have increased dramatically as well. A September 2019 press release from the American College of Rheumatology (ACR) presented results from a survey conducted by the ACR, which found “even though 90 percent of respondents [with rheumatic diseases] reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.” The report also said that nearly 25 percent of respondents had out-of-pocket costs of more than $1,000 per year, while 6 percent reported more than $5,000 per year. Both Curtis and Bose report having patients who do not take their medication as prescribed because of costs, leading to less-than-optimal results.
Failing First: Insurance Provider Demands to Limit Medication Choices
The ACR study also reported that 50 percent of respondents said their medical insurance required the patient go through a step process, in which they are forced to try and fail treatments preferred by the insurance company before trying other options — even when a patient’s doctor doesn’t think the insurer-preferred option will be as effective as a different treatment. Curtis is surprised by the 50 percent data; in his experience, the step process demanded by insurance companies has been 100 percent (meaning that all his patients had to go through the step therapy process). This can lead to a lot of frustrating trials and wasted time during which the disease is progressing.
